We report the outcome of allogeneic bone marrow transplantation (BMT) as treatment for severe combined immunodeficiency disease (SCID) in 31 patients grafted from 1968 until 1992. The patients received a graft from an HLA-identical related (n = 10). an HLA-haplo-identical related (n = 19). or a closely HLA-matched unrelated (n = 2) donor that resulted in the long-term survival of 6 of IO, 9 of 19, and 0 of 2 children, respectively. Major complications included failure of engraftment and early death caused by respiratory failure. The chimerism pattern and immunologic remnstitution were evaluated in 15 children who survived more than 1 year with sustained engraftment. The pattern of engraftment was investigated within flow-sorted peripheral blood (PB) T-and B-lymphoid, natural killer (NK), and myelomonocytic cell populations using the amplification of variable number of tandem repeats by the polymerase chain reaction. The immunologic reconstitution was assessed by various in vitro and in vivo parameters. Although the num-EVERE COMBINED immunodeficiency (SCID) is a heterogeneous group of congenital disorders, characterized by severe impairment of both cellular and humoral immunity, usually leading to death within 2 years of life.'.* Patients with SCID have been treated successfully with HLA identical allogeneic bone marrow transplantation (BMT) since 19683.4 and with HLA haplo-identical T-cell-depleted (TCD) BMT since 198 1 .5 A European survey of the period 1968 to 1989 has shown a probability of survival of 76% and 52% after HLA identical and HLA nonidentical BMT for SCID, respectively.6 Moreover, SCID patients treated after 1983 with an HLA-identical graft showed a probability of survival of 97%: Unfortunately, HLA haplo-identical BMT was frequently associated with failure of engraftment or incomplete immune reconstitution. The use of more intensive conditioning regimens has resulted in a higher frequency of engraftment of B lymphoid and myelomonocytic lineages and improved immunologic reconstitution after HLA haploidentical BMT,6.7 which suggests a relation between en- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "adveaisement" in accordance with 18 U.S.C. section 1734 .solely to indicate this fact.
We report the outcome of allogeneic bone marrow transplantation (BMT) as treatment for severe combined immunodeficiency disease (SCID) in 31 patients grafted from 1968 until 1992. The patients received a graft from an HLA-identical related (n = 10). an HLA-haplo-identical related (n = 19). or a closely HLA-matched unrelated (n = 2) donor that resulted in the long-term survival of 6 of IO, 9 of 19, and 0 of 2 children, respectively. Major complications included failure of engraftment and early death caused by respiratory failure. The chimerism pattern and immunologic remnstitution were evaluated in 15 children who survived more than 1 year with sustained engraftment. The pattern of engraftment was investigated within flow-sorted peripheral blood (PB) T-and B-lymphoid, natural killer (NK), and myelomonocytic cell populations using the amplification of variable number of tandem repeats by the polymerase chain reaction. The immunologic reconstitution was assessed by various in vitro and in vivo parameters. Although the num-EVERE COMBINED immunodeficiency (SCID) is a heterogeneous group of congenital disorders, characterized by severe impairment of both cellular and humoral immunity, usually leading to death within 2 years of life.'.* Patients with SCID have been treated successfully with HLA identical allogeneic bone marrow transplantation (BMT) since 19683. 4 and with HLA haplo-identical T-cell-depleted (TCD) BMT since 198 1 . 5 A European survey of the period 1968 to 1989 has shown a probability of survival of 76% and 52% after HLA identical and HLA nonidentical BMT for SCID, respectively.6 Moreover, SCID patients treated after 1983 with an HLA-identical graft showed a probability of survival of 97%: Unfortunately, HLA haplo-identical BMT was frequently associated with failure of engraftment or incomplete immune reconstitution. The use of more intensive conditioning regimens has resulted in a higher frequency of engraftment of B lymphoid and myelomonocytic lineages and improved immunologic reconstitution after HLA haploidentical BMT,6.7 which suggests a relation between en-ber of PB T cells and the in vitro T-cell proliferative response was in the lower region of normal in the majority of cases and even subnormal in some, in all cases donor T-cell engraftment and reconstitution of T-cell immunity was observed. Residual host-type T cells (1% t o 5%) were detected in eight cases at multiple occasions. All children showed normal serum IgM and IgG subclass levels and produced specific IgG antibodies after vaccination, irrespective of donor B-cell engraftment. However, three HLA haplo-identical graft recipients with host-type B lymphoid and myeloid cells have a persistent selective IgA deficiency. NK cells were either of donor, host, or mixed origin. Donor NK cell engraftment restored defective in vitro NK cell function of the recipient. We conclude that determination of lineage-specific engraftment patterns provides valuable information for the understanding of the immunologic reconstitution after allogeneic BMT for SCID.
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graftment of hematopoietic non-T-cell lineages and immunologic reconstitution.
We have evaluated the outcome of 31 consecutive cases of allogeneic BMT for SCID performed at the Department of Pediatrics of the Leiden University Hospital. To define the basis of incomplete immune reconstitution after allogeneic BMT for SCID, we determined (1) the degree of engraftment of different hematopoietic cell lineages using fluorescence-activated cell sorting (FACS) and amplification of highly polymorphic variable number of tandem repeats (VNTRs) by the polymerase chain reaction (PCR),8.9 and (2) the immunologic reconstitution by a variety of in vivo and in vitro parameters in 15 cases who showed sustained engraftment and survived more than 1 year after BMT.
MATERIALS AND METHODS

Patients.
From December 1968 until July 1992, 47 infants and young children suffering from SCID were referred to the Department of Pediatrics of the Leiden University Hospital for treatment. Eleven of these patients died before transplantation could be performed. Five patients, who lacked a suitable donor and were treated with fetal liver cell transplantation before 1978, died without immunologic reconstitution."' The remaining 31 patients, included in this study, were treated by allogeneic BMT. Data were collected until July 1993, giving a minimum follow-up of I year for all children. This study was approved by the Institutional Review Board on Medical Ethics.
Patients were classified according to criteria of the World Health Organization" into one of the following categories: SCID with a low number of T and B cells (T-B-), SCID with a low number of T cells, but a normal number of B cells (T-B'), SCID caused by adenosine deaminase deficiency (ADA-), Omenn's syndrome (OS), and HLA class I1 deficiency ( 2  5  17  26  50  74  92  105  131  139  4  28  41  53  56  59  81  82  93  94  96  108  112  114  118  126  167  168  183  189  199   M14  MI1  F11 5  F14  F15  F144  MI6  F182  MI1  F146  MI7  MI9  MI1  MI4  F13  M16  F156  F142  M P l  F11 4  F12  MI8  MI4  MI6  M P  M18  F19  F16  F14  MI1 
Class 11-
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Class IIClass II- The majority of the patients presented with diarrhea, failure to thrive, and recurrent or persistent infections of the respiratory tract (eg, with Pneurnocystis carinii), digestive tract (eg, with rotavirus), mucosa, and/or skin (eg, with C albicans and Staphylococcus aurew). All patients showed an absent or severely decreased in vitro T-cell response towards phytohemagglutinin (PHA) (data not shown).
ADA-T-B'
T-B' T-B' OSt
BMT. Transplant-related variables are listed in Table 2 . Patients received a BM graft from an HLA-identical related (n = lo), an HLA-haplo-identical related (n = 19) or a closely HLA-matched unrelated (n = 2) donor. Retransplantations were undertaken in six cases because of lack of engraftment and immune reconstitution after a previous attempt. The date of the most recent attempt of BMT is considered day 0. Conditioning of the patients was performed according to protocols formulated by the European Group for Immunodeficiency (EGID) and the European Group for Bone Marrow Transplantation (EBMT) ( Abbreviations: RID, recipient/donor; HLA disp, disparity for HLA A, B, and DR antigens on the noninherited haplotype; ATG, 2 mg/kg body weight (BW) x 3 (days -6 through -4); Camp, Campath-IG MoAb at 0.2 mg/kg BW x 2 (days -5 and +3) plus Campath-IM MoAb at 0.2 mg/ kg BW x 1 (day 0); LFA1, 0.2 mg/kg BW x 13 (days -3 through +lo); CD2, 0.2 mglkg BW x 11 (days -2 through +8); VPlGW0, total dose of etoposide in mg/m2; Buwlsno, total busulfan dose in mg/kg BW; Cy~ow12ww, total dose of cyclophosphamide in mglkg BW; TBIw, total-body irradiation dose in Gy; na, not applicable; A(W), alive (and well); FU, follow-up; VOD, veno-occlusive disease; AdV, adenovirus; MTX, methotrexate; CsA, cyclosporin A; Propho, prophylaxis; TCD, T-cell depletion. (Table 2) . HLA-identical graft recipients received albumin gradienvstem cell-enriched l-log TCD BM.23 The majority of HLA-non-identical allograft recipients received more than 2-log TCD BM cells after albumin gradient and E-rosette ~eparation?~ or after treatment with Campath-1M MoAb plus human complement.2s Additional graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CsA), 2 m&g/d intravenously (day -5 to +30, followed by 6 mg/kg/d orally through day +l201 and tapered off until discontinuation at day + 180, or methotrexate (Mtx) intravenously at weekly intervals up to day + 102.26 All patients were nursed within the environment of a laminar flow isolator and received prophylactic antimicrobial medication to suppress their intestinal mi~roflora.'~ Chimerism analysis. Chimerism analysis of fractionated peripheral blood mononuclear cells (PBMCs), obtained after Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) density-gradient centrifugation, was performed after cell sorting followed by amplification of VNTRs by PCR, so called FACS/PCR-INTR or FPV a n a l y~i s .~,~ CD3+CD4+ and CD3+CD8+ T cells, CD20TD19' B cells, CD16+CD14-natural killer (NK) cells and CD14+CD16-myelomonocytic cell populations were investigated. Two children could not be evaluated by FPV analysis either because of technical reasons (UPN 108) or because none of the 5 VNTR markers yielded patient and/or donor-specific alleles (UPN 131). In these cases, a sex mismatch between the donor and the recipient permitted analysis by fluorescent in situ hybridization with a Y-chromosome-specific probe (Y-FISH) in combination with simultaneous fluorescent labeling of cell surface antigens." Ig allotypes were determined in a hemagglutination inhibition assay?9
Immunologic teesrs. Immunophenotypic analysis of PBMCs was performed by two-color immunofluorescence microscopy or by flowcytometric analysis using a FACStar flow cytometer and commercially available MoAb in appropriate dilutions. From 1 year after BMT onwards, investigations were performed at irregular time intervals. Age-matched reference values for PB counts of lymphocytes, CD3' T cells, surface Ig+ (sIg+), or CD20+ B cells and CD16+ NK cells (5% to 95% confidence intervals) were kindly provided by Professor Dr J.J.M. van Dongen (Erasmus University Rotterdam, The Netherlands). Serum Ig isotype and IgG subclass levels were determined by radial immunodiffusion and dot immunobinding assay, respectively, and compared with age-matched reference values ( 2 2 SD).30 in vitro T-cell proliferative capacity was assessed either in whole blood or in standard PBMCs using microculture techniques following mitogenic (PHA and/or antilymphocyte serum [ALS]), allogeneic (mixed lymphocyte culture [MLC]), or pseudoantigenic (anti-CD3) stimuli and compared with normal reference values (5% to 95% confidence intervals)?' In vitro NK cell function was measured by spontaneous cytotoxicity towards the K562 erythroleukemia cell line in standard 4-hour 5'Cr release assays and compared with reference values (10% to 90% confidence intervals)." Specific IgG antibody production was determined in serum taken 2 to 4 weeks after in vivo immunization with diphtheria toxoid (D), tetanus toxoid (T), and heat-inactivated poliomyelitis (P) virus type I, 11, and 111 (DT-IPV) vaccine using routine techniques at the National Institute of Public Health and Environmental Protection (NIPHEP, Bilthoven, The Netherlands). The children received the DT-IPV injections at irregular time intervals after BMT. Data obtained within 1 month after discontinuation of daily plasma infusions or biweekly intravenous immunoglobulin (IVIG) therapy were excluded from analysis. Control groups consisted of 20 healthy infants and 20 children who received an HLA-identical BM graft for leukemia. Healthy infants received DT-IPV vaccine (I through IV) at 3, 4, 5, and 11 to 14 months of age. Data of these infants were kindly provided by Dr H. RUmke (NIPHEP). Leukemia patients received DT-IPV vaccine (I through IV) at 2, 3, 4, and 6 to 24 months after HLA-identical BMT. Data of leukemic graft recipients were kindly provided by Dr J. Labadie (Department of Pediatrics, Leiden University Hospital, Leiden, The Netherlands).
RESULTS
MaternoTfetal T-cell engraftment.
Materno-fetal T-cell engraftment was only looked for in typical SCID patients (ie, with T-B-, T-B+, or ADA-type SCID) in case the absolute PB CD3+ T-cell count was more then 200/pL at admission (n = 4). This was performed by HLA class I serotyping of E-rosette-positive T cells and by FPV analysis of PBMCs. Maternal T cells were detected by both techniques in two patients (UPN 56 and 59) who also showed clinical signs of GVHD at diagnosis. Maternal T cells were absent in one other patient (UPN 17), and no material was available for analysis in the fourth case (UPN 26). Using FPV chimerism analysis, we also excluded the presence of circulating maternal T cells in one patient with OS (UPN 183).
Transplant outcome. Transplant-related variables and clinical outcome are listed in Table 2 . Engraftment could not be evaluated in five children who died within 21 days after BMT. Successful engraftment after the first BMT was obtained in 17 of 26 evaluable children. In 4 of 9 cases with primary graft failure, sustained engraftment was obtained after a second transplant (following intensification of the conditioning regimen). These cases included three patients who did not receive cytoreductive treatment before the first BMT (UPN 17,50 and 53), and one patient (UPN 92) who showed residual alloreactivity and expressed no adverse clinical symptoms after BCG vaccination and transfusion with nonirradiated blood products before BMT. The other 5 cases of primary graft failure were observed after HLA-haploidentical TCD BMT, despite the use of high-dose myeloablative conditioning. Strikingly, the children with atypical T-B-SCID (UPN 81 and 82) showed repeated graft failure, even after infusion of Campath MoAbs in vivo and conditioning with total-body irradiation. Additional attempts of grafting were not undertaken in the remaining cases of graft failure, ie, in two siblings with HLA class I1 deficiency (UPN 93 and 94) and in one infant with atypical OS who showed a normal response in MLC before BMT (UPN 118), either because of parental refusal (UPN 93 and 94) or because the patient had suffered from severe veno-occlusive disease after BMT (UPN 118). UPN 94 ultimately died after a second transplant performed elsewhere.
The actual survival percentage after HLA-identical related, HLA-haplo-identical related, and closely HLAmatched unrelated BMT was 60% (6/10), 47% (9/19), and 0% (0/2), respectively. As seen in Table 2 , major causes of death were primary graft failure (n = 5) and respiratory failure (n = 5). All children who died from respiratory failure presented with severe and progressive lung infection (P carinii, Aspergillus or cytomegalovirus) before BMT.
With the exception of three cases (UPNs 2, 53, and 56), all long-term survivors are alive and well (Kamofski score, 100%; Table 2 ). UPN 2 suffered from recurrent skin infec- tions caused by S aureus in association with acne and warts, and experienced a severe S aureus sepsis and pneumonia once, at the age of 7 years; he is now under flucloxacillin prophylaxis. UPN 53 suffered from recurrent upper respiratory tract infections (URTI) with encapsulated bacteria until the age of about 10 years; he is now scheduled for tympanoplasty of both ears; he still suffers from warts on feet and hands. UPN 56 recovered from her extensive chronic GVHD of the skin, except for persisting hypopigmentation of skin and hair. Chimerism patterns. Lineage-specific patterns of engraftment and immune reconstitution were evaluated in 15 of 16 children who survived more than 1 year after BMT with sustained engraftment. UPN 5, who showed complete immune reconstitution, but lacked engraftment in B lymphoid and erythroid lineages,33 was lost to follow-up and could not be evaluated. PB T cells were exclusively or predominantly of donor origin in all children, whereas B -, NK-and myeloid cell populations were either of recipient, donor, or mixed origin (Table 3 and Fig l, A through C,  last follow-up) . Surprisingly, residual (1% to 5%) host T cells were detected in eight cases up to 23 years after BMT. Except for UPN 2 and 105, these residual host-type T cells were detected at multiple occasions. In three cases who received no conditioning before BMT, engraftment of the myeloid cell lineage was absent or extremely limited. In addition, myeloid cells remained predominantly of host origin in 7 of 12 children who received prior cytoreductive treatment. Five children showed (complete) engraftment in all cell lineages.
The origin of serum Igs after BMT was evaluated by Ig allotyping. Unfortunately, a discriminating Ig allotype marker was not available in 12 of 15 donorhecipient pairs.
Both donor and recipient Ig allotypes were detected in the serum of UPN 17, and recipient Ig allotypes were found in the serum of UPN 53 and 59 (data not shown), in agreement with the results obtained by FPV analysis.
PB lymphocyte numbers. Longitudinal analysis of the absolute numbers of various PB lymphocyte subsets showed considerable fluctuations of cell counts in the children who were frequently investigated. Results of the last follow-up are summarized in Table 4 . We repeatedly observed subnormal absolute lymphocyte and CD3' T-cell counts in five cases (UPN 2, 53, 56, 131, and 168), although they were incidentally within normal range for UPN 2 and 56 at the last follow-up. In general, decreased counts were observed in both CD4' and CD8' T-cell subsets in graft recipients with a diminished number of CD3' T cells. Three children (UPN 2, 56, and 105) showed an increased percentage of y6 T lymphocytes at the last evaluation (40%, 17%, and 19%, respectively). Although UPN 168 and 183 repeatedly showed a decreased number of circulating B cells, the absolute numbers of CD16+ NK and CD20' and/or sIg+ B cells were within the normal range in the majority of cases.
In vitro T-cell proliferation.
Analyses were performed at irregular time intervals after BMT. The results of the last investigation are summarized in Table 4 . The in vitro proliferative T-cell response towards PHA, ALS, and anti-CD3 MoAb in whole blood cultures and the response towards PHA in standard PBMC cultures was repeatedly decreased in three children (UPN 2, 53, and 131) . The in vitro T-cell response towards alloantigens, as determined in the MLC, was decreased at multiple occasions in one case (UPN 53).
B-cell immune reconstitution. Longitudinal analysis of serum Ig classes and IgG subclasses was performed from 1
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All evaluable children (n = 14) who survived more than 1 year after BMT with sustained engraftment showed a positive IgG antibody response towards at least one T-cell-dependent recall antigen after repeated DT-IPV immunizations posttransplant ( Table 5) . UPN 199 was considered nonevaluable because he received only two injections of DT-IPV vaccine and has not yet produced specific IgG antibodies towards any of the DT-IPV antigens. Although UPN 59 did not respond to D or IPVI.III antigens, even after 6 DT-IPV injections, he produced specific IgG antibodies toward tetanus, and toward rubella after natural infection (data not shown).
As seen in Table 6 , the cumulative response rates of the grafted SCID patients towards DT-IPV antigens, as observed within 6 months after BMT, are inferior to those of healthy infants, but comparable to those observed after BMT for leukemia. In this context, it should be noted that the majority of graft recipients received immunosuppressive therapy up to 6 months posttransplant, which may explain the poorer specific antibody responses when compared with healthy infants. Additional immunization with DT-IPV vaccine more than 6 months after BMT for SCID further increased the cumulative response rate: graft recipients who received at least a total of four injections of DT-IPV vaccine or showed a positive antibody response after previous vaccination showed a cumulative response rate towards D, T, IPV,, IPVII, and IPVlll of 75% (9/12), 100% (l3/13), 92% (l2/13), 85% (1 1/13), and 75% (9/12), respectively ( Table 5 ). In comparison, healthy infants exhibit a 100% cumulative response rate toward DT-IPV antigens from DT-IPV IV onward, and children grafted for leukemia exhibit a 100% cumulative response rate toward tetanus toxoid from DT-IPV IV onward.23a
In vitro NK cell function. The in vitro NK cell function of the children after BMT is summarized in Table 4 and Fig 2. Engraftment of donor NK cells was associated with restoration of NK cell activity in two graft recipients with a defective NK cell function before BMT (UPN 1 12 and 131) . Although NK cells were completely of donor origin, UPN 126 showed decreased in vitro NK cell activity. The in vitro NK cell function of this patient before BMT was not determined. The NK cell function was only partially restored in three graft recipients (UPN 2, 17, and 59), perhaps because in these children, a mixture of functionally defective recipient NK cells and normal donor NK cells was present after BMT. None of the latter cases received cytoreductive treatment before BMT. We also observed normal NK cell activity in transplant recipients without or with only marginal NK cell engraftment (UPN 53, 56, 168, and 183). This finding is in agreement with the normal NK cell activity observed before BMT in three of these cases (UPN 53, 56, and 168). year after BMT onwards. Three children (UPN 53, 59 and 199) showed a persistent selective IgA deficiency (IgA-D) after BMT. Some secretory IgA was detected in the tears of UPN 53, but not in those of UPN 59. In several of the other cases, serum levels of total IgG, IgG subclasses and IgA occasionally dropped below the lower confidence limit (-2 SD) of age-matched controls, but none of them showed a persistent deficiency in these subclasses ( t Below fifth percentile of control values, ie <6,000 counts per minute (cpm) for PHA, <14,000 cpm for ALS, and <l600 cpm for a-CD3." * Below 2.5 percentile of control values, ie, <8,400 c p~n .~' § Response capacity, percent of two controls (250% is considered normal).
/I Above (N) cq below (1) 10th percentile of controls32 (see also Fig 2, A through D) .
The actual survival is 60% after HLA-identical BMT (n = the actual survival after HLA identical and HLA non-identilo), 47% after HLA-haplo-identical BMT (n = 19) and 0% cal BMT for SCID is 67% and 53%, respectively. Similar after closely HLA-matched unrelated BMT (n = 2). If paprobabilities of survival have been reported by the EBMT tients with HLA class I1 deficiency or OS, disorders associin the 1968-1989 survey (ie, 76% and 52% after HLA-identiated with a poor prognosis,34 are excluded from our report, cal and HLA-nonidentical BMT, respectively).6 Major obsta- For Response to either IPV,, IPV,,, or IPV,,,.
t Number of patients who showed a positive response among those who either received three DT-IPV injections or showed a positive response after previous vaccination within 6 months after BMT.
cles for short-term success were early death caused by respiratory failure (n = 5), and primary graft failure (n = 9) ultimately leading to death in five cases. The children who died from respiratory failure all presented with progressive lung infection before BMT, an important adverse risk factor in the EBMT survey: Graft failure was observed after unconditioned BMT (n = 3) and, despite prior cytoreductive treatment, in patients with T-B+ SCID (n = l), atypical OS (n = 1) ; ' atypical T-B-SCID (n = 2),12 and HLA class I1
A.
' " 1 deficiency (n = 2). Successful engraftment was obtained in four of six patients who received a second transplant.
Sixteen graft recipients were alive for more than 1 year after BMT, and data on these cases are included in this evaluation (except for UPN 5, who was lost to follow-up). With the exception of an episode of severe S aureus infection in UPN 2, recurrent URTI in UPN 53, and persistenthecurrent warts in both cases, no signs or symptoms of a subnormal immunologic defense capacity were present in the long- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From term survivors at a median (range) follow-up of 6 (1 to 24) years after BMT. None of the children received Ig suppletion more than 6 months after BMT. Except for UPN 2, who is on flucloxacillin prophylaxis for his tendency to develop S aureus skin infection, none of the long-term survivors received antimicrobial prophylaxis more than 6 months after BMT.
In 15 children and young adults, we investigated the relationship between engraftment of different cell lineages and immune reconstitution. In the majority of cases, FPV chimerism analysis showed the presence of complex, cell lineage specific patterns of engraftment, which are not observed after high-dose conditioning and allogeneic BMT for le~kemia.'.'~ Interestingly, conditioning with busulfan (8 to 16 mgikg BW) plus cyclophosphamide was not sufficiently myeloablative in the majority of children to eradicate host-type hematopoiesis. In a previous study, we noted a high incidence of persistent host-type hematopoiesis in children less than 2 years of age grafted for leukemia after conditioning with busulfan (16 to 24 mgikg BW) plus cy~lophosphamide.~~ These findings may be explained by altered pharmacokinetics of busulfan in children as compared with adults leading to decreased drug exposure in children? Thus, the use of either no or a relatively mild preparative regimen before BMT for SCID leads to the persistence of host-type stem cells. In turn, these may occupy the space in the BM necessary for engraftment of donor stem cells. Under these circumstances, donor cells may be detectable only at the maturational stage of the hematopoietic cell lineages in which recipient cells have defects in their development andor function as a result of a selective growth advantage.
Surprisingly, we detected residual (1% to 5%) host-type T cells in eight of the graft recipients, even more than 23 years after BMT. Although we cannot formally exclude the possibility that purified T cells might have been contaminated with recipient non-T cells, we believe that this explanation is unlikely for several reasons. First, all T-cell populations that were purified by cell sorting showed a clearly distinct staining pattern in fluorescence diagrams (results not shown). Second, residual host-type T cells were observed in some, but not all children with cell lineage-specific engraftment patterns; these host-type T cells were detected on several occasions in all six children who were investigated more than once. Moreover, residual host-type T cells were detected in one child with predominantly donor cells in non-T-cell lineages (UPN 105). It seems unlikely that the persistence of residual host-type T cells can be confirmed by standard metaphase cytogenetics because, in our experience, FPV chimerism analysis is more sensitive and because these host-type T cells most likely do not respond to polyclonal activators (eg, PHA) used to obtain metaphases for karyotyping. In addition, informative cytogenetic markers were not available in several of these cases.
All children who showed sustained engraftment and survived for more than 1 year after BMT showed significant improvement of T-cell immunity as evidenced by several in vivo and in vitro parameters. However, we found that a number of long-term survivors continued to have low absolute T cell counts and low in vitro proliferative T-cell responses for many years after BMT, in contrast to the observations of Wijnaendts et al. 37 Defective in vitro NK cell function in SCID patients beand nonrandom X-chromosome inactivation in NK cells of female obligate XSCID carriers4" has been described, suggesting that NK cells are intrinsically defective in a subset of patients with SCID. Here, we show that NK cells can be either of recipient, donor, or mixed origin. Donor T-and B-cell engraftment was not always associated with donor NK cell engraftment, supporting the idea that NK cells belong to a separate lymphoid lineage. All evaluable children showed in vitro NK cell activity after BMT. Importantly, engraftment of NK cells was associated with increased in vitro NK cell function in children who showed defective in vitro NK cell activity before BMT. Accordingly, incomplete NK cell engraftment resulted in partial restoration of in vitro NK cell function in such cases.
All children with sustained engraftment showed evidence of humoral immune reconstitution after BMT. None of the children showed a persistent Ig isotype deficiency, except for three cases (UPN 53, 59, and 199) who lacked B-cell engraftment and displayed a long-lasting selective IgA-D after BMT for T-B' SCID. Selective IgA-D after HLAhaplo-identical BMT for SCID has been reported also by other investigator^."^^' Importantly, specific IgG antibodies were detected in all evaluable children after repeated DT-IPV immunization (and after natural infection), irrespective of donor B-cell engraftment. However, the recovery of specific antibody synthesis after BMT for SCID may not be complete in all cases as suggested by holes in the antibody responses after repeated vaccination (eg, in the case of UPN 59; Table 5 ). Interestingly, the cumulative response rates towards DT-IPV antigens of the group of grafted SCID patients were similar to those observed in children after HLAidentical BMT for leukemia (Table 6) .
A European survey has shown that incomplete humoral immune reconstitution (ie, lack of specific antibody production or Ig isotype deficiency) after HLA nonidentical BMT for SCID is strongly associated with failure of B-cell engraftment.'j In agreement with these data, we only observed incomplete humoral immune reconstitution (ie, selective IgA-D) in children who showed no or only marginal Bcell engraftment after HLA-haplo-identical BMT for T-B' SCID. Several mechanisms, which are not mutually exclusive, may explain the above findings. First, lack of B-cell engraftment may lead to incomplete humoral immune reconstitution after BMT for T-B' SCID, because subtle defects in in vitro B-cell function have been described in a subset of T-B+ SCID patients42 and because nonrandom X-chromosome inactivation has been observed in B lymphocytes obtained from female obligate XSCID carriers, suggesting an intrinsic B-cell defect.47 More recently, it has been shown that XSCID is caused by mutations in the common y ( y J chain,44 a functionally important component of the IL-2, IL-4, and IL-7 receptors.ds-4R Thus, we cannot exclude the possibility that the persistent host-type B cells of children with incomplete humoral immune reconstitution (UPN 53, 59, and 199) are intrinsically defective for some, but not all, Bcell functions. However, the hypothesis described above fore BMT32.38.39
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From does not explain the general finding that incomplete humoral immune reconstitution is observed almost exclusively after HLA nonidentical BMT.6.7.37,49
Second, incomplete humoral immune reconstitution after HLA-nonidentical BMT may be caused by the inability of donor T cells to cooperate with host B cells across major histocompatability complex (MHC) barriers. This model seems unlikely for several reasons: (1) postthymic T cells of murine radiation BM chimeras display MHC restriction patterns towards host MHC antigens5's5' because positive selection is mediated by thymic epithelial cells of host MHC gen~type~'-'~; (2) T-B-cell cooperation across MHC barriers has been shown in several SCID patients after HLA-nonidentical BMT, even at the clonal l e~e l~~.~' ;
and (3) T-B-cell cooperation after HLA-haplo-identical BMT can always occur via the shared HLA haplotype.
Third, lack of self-tolerance towards donor-specific HLA HLA class I1 phenotypically identical, MLC-negative, related donor (which was also identical at the HLA DR and DP loci as determined by oligotyping) and showed complete humoral immune reconstitution, whereas the other three graft recipients showed selective IgA-D after HLA class I1 haplomismatched BMT. In these children, expression of donor HLA class I1 antigens is restricted to activated T cells. Although there is no direct evidence showing a causal relationship between the presence of donor-antidonor class I1 reactivity and incomplete humoral immune reconstitution, it seems possible that the presence of donor-antidonor HLA class 11 reactivity in these cases may interfere with T-cell activation, leading to a reduced efficiency of T-B-cell cooperation and incomplete humoral immune reconstitution?* Importantly, such a model provides an explanation for the finding that incomplete humoral immune reconstitution is found almost exclusively after HLA-nonidentical BMT and is restricted to graft recipients who lack B lymphoid and myeloid engraftment. 
